BlackRock Inc. purchased a new stake in Embecta Corp. (NASDAQ:EMBC – Get Rating) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 8,984,936 shares of the company’s stock, valued at approximately $258,676,000. BlackRock Inc. owned 15.53% of Embecta as of its most recent SEC filing.
Other hedge funds and other institutional investors have also modified their holdings of the company. Whittier Trust Co. of Nevada Inc. purchased a new stake in Embecta during the third quarter valued at about $27,000. Copeland Capital Management LLC acquired a new stake in Embecta during the 3rd quarter valued at $28,000. Lazard Asset Management LLC purchased a new stake in shares of Embecta in the third quarter valued at $31,000. Russell Investments Group Ltd. purchased a new position in shares of Embecta during the third quarter valued at $32,000. Finally, Northwest Investment Counselors LLC acquired a new position in Embecta during the third quarter valued at $36,000. Institutional investors and hedge funds own 93.45% of the company’s stock.
Embecta Stock Down 0.6 %
NASDAQ EMBC opened at $30.27 on Monday. The firm’s fifty day simple moving average is $27.96 and its 200-day simple moving average is $29.74. Embecta Corp. has a 1-year low of $22.30 and a 1-year high of $49.00.
Embecta Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Monday, March 13th. Stockholders of record on Monday, February 27th will be issued a dividend of $0.15 per share. The ex-dividend date of this dividend is Friday, February 24th. This represents a $0.60 dividend on an annualized basis and a dividend yield of 1.98%.
Insider Buying and Selling
In other Embecta news, Director David F. Melcher bought 3,100 shares of the stock in a transaction on Wednesday, February 15th. The shares were purchased at an average cost of $32.51 per share, with a total value of $100,781.00. Following the completion of the transaction, the director now directly owns 21,465 shares of the company’s stock, valued at approximately $697,827.15. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. 0.22% of the stock is currently owned by corporate insiders.
Wall Street Analysts Forecast Growth
Separately, Morgan Stanley cut Embecta from an “equal weight” rating to an “underweight” rating and set a $28.00 target price on the stock. in a research note on Friday, January 6th.
Embecta Company Profile
Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety devices, as well as digital applications to assist people with managing their diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally.
- Get a free copy of the StockNews.com research report on Embecta (EMBC)
- What the SVB Financial Collapse Means for U.S. Banks
- MarketBeat Week in Review – 3/6 – 3/10
- 2 Offshore Drilling Stocks Set to Extract Big Profits
- Three Staples Stocks With Double-Digit Upside Ahead
- Can Investors Trust Consumers to Lift American Outdoor Brands?
Receive News & Ratings for Embecta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Embecta and related companies with MarketBeat.com's FREE daily email newsletter.